Table 3.
Subgroup Analysis of the Change in HbA1c in Response to Metreleptin Treatment in GLD and PLD Patients
| Subgroup | Generalized Lipodystrophy |
Partial Lipodystrophy |
||||||
|---|---|---|---|---|---|---|---|---|
| 0 mo HbA1c, % | 6 mo HbA1c, % | 12 mo HbA1c, % | P Value | 0 mo HbA1c, % | 6 mo HbA1c, % | 12 mo HbA1c, % | P Value | |
| Baseline HbA1c > 8% (GLD, n = 34; PLD, n = 14) | 9.8 (1.4) | 7.1 (1.8) | 6.9 (1.5) | <.001 | 10.1 (1.6) | 7.9 (1.2) | 8.3 (1.9) | <.001 |
| Baseline HbA1c > 7% (GLD, n = 40; PLD, n = 20) | 9.4 (1.6) | 7.0 (1.7) | 6.8 (1.5) | <.001 | 9.3 (1.8) | 7.8 (1.1) | 8.1 (1.7) | .002 |
| Baseline HbA1c < 8% (GLD, n = 22; PLD, n = 17) | 6.1 (1.2) | 5.6 (1.1) | 5.5 (0.8) | .002 | 6.5 (0.9) | 6.8 (1.2) | 6.5 (0.9) | .81 |
| Baseline leptin < 4 ng/mL (PLD, n = 10) | 8.8 (2.6) | 7.1 (1.7) | 7.3 (2.2) | .04 | ||||
| Baseline leptin > 4 ng/mL (PLD, n = 21) | 7.8 (2.0) | 7.3 (1.1) | 7.3 (1.4) | .15 | ||||
Data are mean (SD). P value is for the effect of metreleptin over time.